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Microvesicle particles (MVP) are 100-1000 nm vesicles that bud from the cell 
membrane and transmit intercellular signals locally and systemically via their 
bioactive cargo (e.g. cytokines). We have previously shown that thermal burn 
injury or UVB radiation result in the formation Platelet Activating Factor (PAF), and 
UVB or a PAF agonist (CPAF) can promote MVP formation in keratinocytes. 
Thermal burn and UVB radiation can result in systemic effects, even though their 
injury is localized to the skin. We therefore propose that PAF-producing injuries, 
UVB irradiation or thermal burn injury, result in the formation of MVPs that can 
potentially transport cytokines through the blood stream and induce systemic 
effects. This study, in-part, addresses that proposed mechanism by demonstrating 
increased MVP release after thermal burn injury in vivo and ex vivo. In vivo there 
was a significant increase in MVP concentration in mouse skin that received 
thermal burn injury compared to untreated skin. This demonstrates that there is 
an increase in MVP release after injury in living models. Human skin explants that 
received suction blisters to separate the epidermis from the dermis exhibited 
increased MVP release into the blister fluid in response to CPAF, UVB or thermal 
burn injury as compared to controls, suggesting epidermal MVPs are mobile and 
can exit the epidermis. Acid Sphingomyelinase (aSMase), an enzyme that breaks 
sphingomyelin into ceramide and phosphorylcholine, has been found to be 
involved in MVP release in other cell types. Utilizing an FDA approved aSMase
inhibitor, Imipramine, we found that UVB, CPAF and thermal burn-mediated MVP 
release is completely dependent on aSMase in keratinocyte cell lines and human 
explant skin. These results suggest that PAF-producing skin injuries (thermal burn 
and UVB) can induce MVP release, and the release can be therapeutically 
inhibited by imipramine.
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MVP Release Increases 
After Injury ex vivo
Results: Blister Method
Various Treatments 
Increase MVP Release 
ASMase Inhibitor Blocks 
MVP Release ex vivo
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Thermal Burn injury in vivo 
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vivo 
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vivo 
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vivo 
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• There was a significant increase in MVP concentration in mouse skin after 
thermal burn injury.  
• This demonstrates that there is an increase in MVP release after 
injury in living models.
• CPAF, UVB and thermal burn injury on human ex vivo skin does increase the 
amount of MVP release compared to untreated skin.
• When the roof of a blister is damaged with thermal burn injury there is increased 
MVP in the blister fluid compared to untreated blisters. 
• This demonstrates that MVP were derived from the epidermis and 
are traveling to the dermis.
• Thermal Burn, UVB and CPAF seem to involve different mechanisms in MVP 
release.
• For burn treatment this mechanism seems to involve NF- B, 
ERK1/2, Jun-kinase, and p38.
• For UVB treatment this mechanism seems to involve Jun-kinase, 
p38, and Rho kinases. 
• For CPAF treatment this mechanism seems to involve NF- B, 
ERK1/2, Jun-kinase, p38, and Rho kinases. 
• For all three treatments (CPAF, UVB, and thermal burn), the increase in MVP 
release seem to be completely dependent on aSMase. 
• As these MVP carry bioactive substances that may be regulating systemic effects 
of UVB and thermal burn, aSMase inhibitors like imipramine may be a potential 
therapeutic agent to prevent these effects. 
Mouse Model: C57BL/6 EGFP Wild type mice 
Human Explant Tissue Model : Abdominoplasty, brechioplasty, and gynecomastia skin were 
graciously donated from Sycamore Medical Center (Miamisburg, OH).  Patients (n=25) were between the 
ages of (23-65).
Treatments: Ø, Vehicle, .29 ng topical CPAF, 2,800 J/m2 UVB, or 5 seconds thermal burn with 90° C water.  
• Inhibitors: Inhibitors were applied topically in 90% DMSO/ 10% EtOH (1.64 μg PDTC, 2.67 μg 
PD98,059, 0.22 μg SP600125, 3.77 μg SB203580, 0.32 μg Y27632, 11.22 μg Z-VAD-FMK, or 1.58 μg 
imipramine). The inhibitors were incubated for 1 hour before proceeding to treatments.
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though 
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Punch Biopsy 
Overnight 
Collagenase/ 
dispase digestion
• Punch Biopsies Method: 
• Blister Method:
Cut skin into small 
pieces. Treat skin and 
incubate 4 hours
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dispase digestion
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Treat skin and
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Remove blister
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